Recruiting

HCV Elimination

Sponsor:

UCLA

Code:

NCT03551002

Conditions

Hepatitis C

Hepatitis C, Chronic

HIV/AIDS

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

A retrospective and prospective study among people living with HIV (PLWH) that assesses hepatitis C (HCV) treatment uptake during periods before and after direct acting antivirals (DAA) introduction, and its impact on the HCV epidemic among PLWH.

Conditions

Hepatitis C

Hepatitis C, Chronic

HIV/AIDS

Study ID

NCT03551002

Start date

Jan 1, 2018

Status verified date

Sep, 2021

Completion date

Dec 31, 2021

Anticipated

Primary completion date

Dec 31, 2021

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Any adult (≥ 18 years) HIV-infected patient attending the UCSD Owen Clinic
  • With history of acute or chronic HCV infection defined as having a detectable HCV viral load with or without a positive HCV antibody

Exclusion Criteria:

  • With no history of or current HCV infection defined as having a negative HCV antibody from 2008 to 2020

Study Design

Enrollment

450 participants

Anticipated

Interventions and Outcome Measures

Arms

Retrospective

Prospective

Primary outcome measure

  • Annual proportion of HIV-infected patients who initiate direct acting antivirals [ Time Frame: 2014-2020 ]

Central Contacts and Locations

Central contacts

Edward Cachay, MD, MAS

(619)543-3882ecachay@ucsd.edu

Locations

Owen Clinic-University of California, San Diego

Recruiting

San Diego, California, United States, 92103-8186

Contacts

Edward Cachay, MD, MAS

ecachay@ucsd.edu

More Information

Sponsor

University of California, San Diego

Last update posted

Sep 5, 2021

Last verified

Sep, 2021

Keywords

  • HIV
  • Hepatitis C
  • Direct acting antivirals
  • Hepatitis C modeling

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Diego on 2021-09-05.